Stock Track | Definium Therapeutics Soars 5.65% as Trump Executive Order Boosts Psychedelic Drug Sector

Stock Track04-21

Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the White House.

The rally was triggered by President Donald Trump's executive order signed on Saturday, which directs health regulators to accelerate reviews of psychedelic drugs like ibogaine and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.

Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note that the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168677170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 10:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168677170","market":"hk","top_or_hot":-1,"title":"Stock Track | Definium Therapeutics Soars 5.65% as Trump Executive Order Boosts Psychedelic Drug Sector","media":"Stock Track","content":"<p>Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the White House.</p><p>The rally was triggered by President Donald Trump's executive order signed on Saturday, which directs health regulators to accelerate reviews of psychedelic drugs like ibogaine and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.</p><p>Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note that the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Definium Therapeutics Soars 5.65% as Trump Executive Order Boosts Psychedelic Drug Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Definium Therapeutics Soars 5.65% as Trump Executive Order Boosts Psychedelic Drug Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-21 10:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the White House.</p><p>The rally was triggered by President Donald Trump's executive order signed on Saturday, which directs health regulators to accelerate reviews of psychedelic drugs like ibogaine and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.</p><p>Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note that the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1168677170","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168677170","pubTimestamp":1776737240,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"个股追踪|特朗普行政令提振迷幻药板块Definium Therapeutics大涨5.65%","themeId":"b19553a137a2d518dfc18efdd547e678","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"Definium Therapeutics' stock surged 5.65% during Monday's trading session, mirroring gains across the psychedelic drug development sector following a significant regulatory announcement from the White House.The rally was triggered by President Donald Trump's executive order signed on Saturday, which directs health regulators to accelerate reviews of psychedelic drugs like ibogaine and commits $50 million for related research. The order provides regulatory benefits including faster FDA review timelines for breakthrough therapy drugs and enables patient access through the Right to Try Act for experimental treatments.Definium Therapeutics, which is developing LSD-based treatments for major depressive disorder and generalized anxiety disorder currently in Phase 3 trials, stands to benefit directly from these regulatory changes. Analysts note that the executive order represents a substantial reduction in regulatory risk for the emerging psychedelic therapy sector and could lead to faster commercialization timelines for Definium's pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168677170","isCrawlerRequest":true}